GlassScriptPhysician profile
Ketan Gala
NPI 1932381035
$18,010.08
in general payments reported to CMS, 2019-2025
20 companies · $4,896 in 2025
The $4,896 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $5.29 · 2021: $165 · 2022: $6,926 · 2023: $2,008 · 2024: $4,010 · 2025: $4,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,463 · Consulting Fee: $3,195 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,050 · Education: $194 · Travel and Lodging: $11.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.99 |
| Consulting Fee | $3,195.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,050.00 |
| Education | $193.98 |
| Travel and Lodging | $11.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,847.77 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Cardiomems |
| Bridgebio Pharma, INC. | $2,778.72 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $2,397.23 | 2023-2025 | Farxiga, Wainua |
| Impulse Dynamics (USA) INC. | $1,890.55 | 2022-2025 | Optimizer, Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $854.01 | 2023-2025 | |
| Abiomed | $575.97 | 2022-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $376.40 | 2023-2025 | Uptravi, Opsumit |
| Cvrx, INC. | $323.00 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $230.24 | 2023-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.70 | 2020-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $120.30 | 2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $114.91 | 2022-2025 | |
| Pfizer INC. | $110.41 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.97 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $69.73 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $37.57 | 2025 | Event, Mcot |
| Change Healthcare Technologies, LLC | $25.35 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.19 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $14.99 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $14.07 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ketan Gala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.